Analyst Downgrade and Revised Target

J.P. Morgan downgraded Coloplast A/S to underweight from neutral in a note dated 9 September 2026, citing a widening valuation disconnect as the stock failed to reflect a deteriorating earnings profile. The broker cut its December 2027 price target to 377 Danish crowns, down from the previous 484 crowns, implying roughly an 18 % downside from Coloplast’s closing price of 446.70 crowns on 8 September 2026.

Valuation Multiples and Earnings Outlook

According to J.P. Morgan analyst Anchal Verma, who now leads coverage, the shares trade at about 18 times projected 2027 earnings, representing a ~20 % premium to the European med‑tech sector despite earnings‑per‑share (EPS) growth that is ~20 % below the sector average. The broker argues that such a premium would only be justified if EPS growth reached high‑single‑digit to low‑double‑digit percentages, yet it forecasts only 3 % EPS growth for fiscal 2027. Under the new target, the implied trading multiple falls to ~14.5 times, aligning with the broader European med‑tech sector.

Probability‑Weighted Scenario Analysis

The revised target reflects a probability‑weighted approach across three mid‑term guidance scenarios, with the expectation that Coloplast’s new chief executive will revise fiscal‑year results on 3 November 2026:

  • Bear case (40 % probability): Sales‑growth guidance cut to 5‑6 %, margins compress to ~25 % due to growth investments, leading to a 30 % downside and a target price of 313 crowns.
  • Base case (50 % probability): Sales growth of 6‑7 % with steady margins, implying a 10 % downside and a target price of 411 crowns.
  • Bull case (10 % probability): Maintains the current 7‑8 % growth target, suggesting a 3 % upside and a target price of 470 crowns.

Recent Stock Performance and Earnings Deterioration

J.P. Morgan noted that Coloplast’s share price has already fallen ~25 % over the past twelve months. The broker believes the earnings profile continues to deteriorate and anticipates further downgrades, arguing that the stock should trade in line with, or at a discount to, the sector rather than at a premium.

Near‑Term Risks Highlighted

Three immediate concerns were identified:

1. U.S. chronic‑care channel execution – difficulty improving commercial performance amid competition from Convatec.

2. Biologics market softness – continued weakness at Kerecis following reimbursement changes.

3. Cost inflation – EBIT margins have declined by more than 4 percentage points over the last five years.

Revised FY2027 Estimates

  • Adjusted EPS estimate lowered to 27.20 crowns from 27.58 crowns, a 1.4 % reduction.
  • Group sales estimate trimmed to 30.83 billion crowns from 30.958 billion crowns, a 0.4 % decrease.

Risks to the Underweight Rating and Upside Catalysts

The primary risk to the underweight rating is a potential mid‑term guidance reset that could enable the new CEO to execute a turnaround, supporting a re‑rating. Upside risks include a return to high‑single‑digit organic sales growth, margin recovery to around 30 %, improved capital allocation such as reducing leverage below 2 times, and maintaining the current dividend policy.